Brand Spotlight: Novo Nordisk’s Semaglutide
In Vivo’s ‘Brand Spotlight’ provides an in-depth look at individual brands with unique or exemplary product journeys – from novel development programs to formidable commercial strategies.
Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease.
